Economic Impact of a triptan Rx-To-OTC Switch in Six EU Countries

di Millier, Aurelie, Cohen, Joshua, Toumi, Mondher
Pubblicazione 2013

Drug repurposing in pharmaceutical industry and its impact on market access: market access implications

di Murteira, Susana, Millier, Aurélie, Toumi, Mondher
Pubblicato in J Mark Access Health Policy (2014)

Systematic review of pharmacoeconomic models for schizophrenia

di Zhou, Junwen, Millier, Aurélie, Toumi, Mondher
Pubblicato in J Mark Access Health Policy (2018)

Drug reformulations and repositioning in the pharmaceutical industry and their impact on market access: regulatory implications

di Murteira, Susana, Millier, Aurélie, Ghezaiel, Zied, Lamure, Michel
Pubblicato in J Mark Access Health Policy (2014)

Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results

di Zhou, Junwen, Millier, Aurélie, François, Clément, Aballéa, Samuel, Toumi, Mondher
Pubblicato in J Mark Access Health Policy (2019)

Attitudes and beliefs of the French public about schizophrenia and major depression: results from a vignette-based population survey

di Angermeyer, Matthias C, Millier, Aurélie, Rémuzat, Cécile, Refaï, Tarek, Toumi, Mondher
Pubblicazione 2013

Predictive models to estimate utility from clinical questionnaires in schizophrenia: findings from EuroSC

di Siani, Carole, de Peretti, Christian, Millier, Aurélie, Boyer, Laurent, Toumi, Mondher
Pubblicato in Qual Life Res (2015)

Quality of life is predictive of relapse in schizophrenia

di Boyer, Laurent, Millier, Aurelie, Perthame, Emeline, Aballea, Samuel, Auquier, Pascal, Toumi, Mondher
Pubblicazione 2013

A critical literature review of health economic evaluations of rotavirus vaccination

di Aballéa, Samuel, Millier, Aurélie, Quilici, Sibilia, Caroll, Stuart, Petrou, Stavros, Toumi, Mondher
Pubblicazione 2013

Validation of disease states in schizophrenia: comparison of cluster analysis between US and European populations

di Thokagevistk, Katia, Millier, Aurélie, Lenert, Leslie, Sadikhov, Shamil, Moreno, Santiago, Toumi, Mondher
Pubblicato in J Mark Access Health Policy (2016)

Determinants of orphan drugs prices in France: a regression analysis

di Korchagina, Daria, Millier, Aurelie, Vataire, Anne-Lise, Aballea, Samuel, Falissard, Bruno, Toumi, Mondher
Pubblicato in Orphanet J Rare Dis (2017)

Social Preferences for Orphan Drugs: A Discrete Choice Experiment Among the French General Population

di Toumi, Mondher, Millier, Aurélie, Cristeau, Olivier, Thokagevistk-Desroziers, Katia, Dorey, Julie, Aballéa, Samuel
Pubblicato in Front Med (Lausanne) (2020)

Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland

di Soini, Erkki, Virtanen, Outi, Väätäinen, Saku, Briere, Jean-Baptiste, Bowrin, Kevin, Millier, Aurelie
Pubblicato in Adv Ther (2020)

Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK

di Bowrin, Kevin, Briere, Jean-Baptiste, Levy, Pierre, Millier, Aurélie, Tardu, Jean, Toumi, Mondher
Pubblicato in J Mark Access Health Policy (2020)

Analysis of health economics assessment reports for pharmaceuticals in France – understanding the underlying philosophy of CEESP assessment

di Toumi, Mondher, Motrunich, Anastasiia, Millier, Aurélie, Rémuzat, Cécile, Chouaid, Christos, Falissard, Bruno, Aballéa, Samuel
Pubblicato in J Mark Access Health Policy (2017)

Relapse according to antipsychotic treatment in schizophrenic patients: a propensity-adjusted analysis

di Millier, Aurelie, Sarlon, Emmanuelle, Azorin, Jean-Michel, Boyer, Laurent, Aballea, Samuel, Auquier, Pascal, Toumi, Mondher
Pubblicazione 2011

Current process and future path for health economic assessment of pharmaceuticals in France

di Toumi, Mondher, Rémuzat, Cécile, El Hammi, Emna, Millier, Aurélie, Aballéa, Samuel, Chouaid, Christos, Falissard, Bruno
Pubblicato in J Mark Access Health Policy (2015)

Health related quality of life in patients having schizophrenia negative symptoms – a systematic review

di Azaiez, Chiraz, Millier, Aurélie, Lançon, Christophe, Clay, Emilie, Auquier, Pascal, Llorca, Pierre-Michel, Toumi, Mondher
Pubblicato in J Mark Access Health Policy (2018)

Cost analysis of adverse events associated with non-small cell lung cancer management in France

di Chouaid, Christos, Loirat, Delphine, Clay, Emilie, Millier, Aurélie, Godard, Chloé, Fannan, Amira, Lévy-Bachelot, Laurie, Angevin, Eric
Pubblicato in Clinicoecon Outcomes Res (2017)

Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France

di Bowrin, Kevin, Briere, Jean-Baptiste, Fauchier, Laurent, Coleman, Craig, Millier, Aurélie, Toumi, Mondher, Clay, Emilie, Levy, Pierre
Pubblicato in PLoS One (2020)